Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma

Background: Somatic loss of the tumour suppressor RB1 is a common event in tubo-ovarian high-grade serous carcinoma (HGSC), which frequently co-occurs with alterations in homologous recombination DNA repair genes including BRCA1 and BRCA2 (BRCA). We examined whether tumour expression of RB1 was associated with survival across ovarian cancer histotypes (HGSC, endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous carcinoma (LGSC)), and how co-occurrence of germline BRCA pathogenic variants and RB1 loss influences long-term survival in a large series of HGSC. Patients and methods: RB1 protein expression patterns were classified by immunohistochemistry in epithelial ovarian carcinomas of 7436 patients from 20 studies participating in the Ovarian Tumor Tissue Analysis consortium and assessed for associations with overall survival (OS), accounting for patient age at diagnosis and FIGO stage. We examined RB1 expression and germline BRCA status in a subset of 1134 HGSC, and related genotype to survival, tumour infiltrating CD8+ lymphocyte counts and transcriptomic subtypes. Using CRISPR-Cas9, we deleted RB1 in HGSC cell lines with and without BRCA1 mutations to model co-loss with treatment response. We also performed genomic analyses on 126 primary HGSC to explore the molecular characteristics of concurrent homologous recombination deficiency and RB1 loss. Results: RB1 protein loss was most frequent in HGSC (16.4%) and was highly correlated with RB1 mRNA expression. RB1 loss was associated with longer OS in HGSC (hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.66–0.83, P = 6.8 ×10−7), but with poorer prognosis in ENOC (HR 2.17, 95% CI 1.17–4.03, P = 0.0140). Germline BRCA mutations and RB1 loss co-occurred in HGSC (P < 0.0001). Patients with both RB1 loss and germline BRCA mutations had a superior OS (HR 0.38, 95% CI 0.25–0.58, P = 5.2 ×10−6) compared to patients with either alteration alone, and their median OS was three times longer than non-carriers whose tumours retained RB1 expression (9.3 years vs. 3.1 years). Enhanced sensitivity to cisplatin (P < 0.01) and paclitaxel (P < 0.05) was seen in BRCA1 mutated cell lines with RB1 knockout. Among 126 patients with whole-genome and transcriptome sequence data, combined RB1 loss and genomic evidence of homologous recombination deficiency was correlated with transcriptional markers of enhanced interferon response, cell cycle deregulation, and reduced epithelial-mesenchymal transition in primary HGSC. CD8+ lymphocytes were most prevalent in BRCA-deficient HGSC with co-loss of RB1. Conclusions: Co-occurrence of RB1 loss and BRCA mutation was associated with exceptionally long survival in patients with HGSC, potentially due to better treatment response and immune stimulation.


Differential gene expression analysis
Primary tubo-ovarian high-grade serous carcinoma (HGSC) tumour samples were grouped according to RB1 alterations and homologous recombination deficiency (HRD) status, as assessed previously using whole-genome sequencing 1 and the CHORD (Classifier of Homologous Recombination Deficiency) method 2 .Matched RNA sequencing data was previously processed into gene expression counts as part of the prior Multidisciplinary Ovarian Cancer Outcomes Group (MOCOG) study 1 .Differentially expressed protein coding genes were identified between sample groups of interest using DESeq2 3 (v1.26.0), with batch effects accounted for in the model.In addition to characterising the transcriptional profiles of tumours with RB1 alterations and concomitant BRCA1-or BRCA2-type HRD relative to tumours with no alterations, DESeq2 was also used to evaluate alteration-specific transcriptional profiles by incorporating given alterations into the model to remove their signal (each comparison is shown in Supplementary Table 7).
The R package FGSEA 4 (fast gene set enrichment analysis; v1.

Molecular characterisation of cell lines
Complete cell line characterisation details can be found in Supplementary Tables S8 and S9.
The mutation status of genes of interest in AOCS cell lines was determined by either wholegenome 1 or targeted sequencing 6,7 using established pipelines, and in commercial cell lines from published data 8 or The Cancer Cell Line Encyclopaedia in cBioPortal [9][10][11] .BRCA and TP53 variants were classified as pathogenic if they were truncating (nonsense, splice site or frameshift) mutations resulting in early stop codons, or missense variants previously reported as pathogenic in ClinVar 12 or The TP53 Database (R20, July 2019, https://tp53.isb-cgc.org).
CCNE1 copy number in AOCS cell lines was analysed by qPCR in triplicate on LightCycler 480 (Roche) using SYBR Green PCR mix (Applied Biosystems) as described previously 13 .The expression status of RB1 and p16 was evaluated by Western blot (as below) and/or IHC.For IHC, FFPE cell line plugs were established by fixing approximately 6x10 7 cells in 10% Neutral Buffered Formalin (NBF) overnight, transferring them into an agarose gel plug and embedding them in paraffin.Duplicate cores were taken from each cell line plug and assembled in a paraffin block in the fashion of a tissue microarray.Cell line microarrays were sectioned, stained with antibodies (RB1, BD Pharmingen, BD Biosciences, clone G3-245; p16, Roche Ventana, CINtec, clone E6H4) and scored blinded by a pathologist.RB1 was classified as either absent, present or uninterpretable; p16 was interpreted according to a 3-tier scoring system as normal patchy, abnormal absent or abnormal overexpressed.
Briefly, lentiviral transduction was performed using the FgH1t vector co-expressing Cas9, mCherry, and GFP and a doxycycline inducible synthetic guide RNA (sgRNAs) targeting RB1 exon 7 or exon 8 (Supplementary Table S10).After sorting for double positive cells (mCherry and GFP) by flow cytometry, expression of the sgRNA was induced with doxycycline (0.1μg/ml media, Sigma-Aldrich, D3072) for 96 hours, and single cells sorted into 96-well plates.Clones were expanded and RB1 status confirmed by reduced/absent RB1 expression (Western blot, RT-qPCR) and Sanger sequencing of the targeted RB1 exon.For control lines, RB1 wild-type single cell colonies without a CRISPR-edit were used, as well as heterogeneous cell populations with transduced Cas9 and sgRNA of a scrambled DNA sequence 15 (Supplementary Table S10).
Nucleofection was conducted with CL-120 Program in 4D-Nucleofector X unit (Lonza Bioscience).Pre-warmed medium was added to cells and incubated for 10 minutes in a humidified 37°C incubator with 5% CO2.Cells were transferred into 6-well plates and cultured.
Each cell line (AOCS30 NT, AOCS30 BRCA1KO, AOCS30 RB1KO, AOCS30 RB1BRCA1KO) was passaged two times to expand following nucleofection, passed through a cell strainer (Falcon 40µm) and plated at a low density (approximately 400 cells per 10cm dish).After ~14 days, independent colonies were trypsinised with cloning discs (Sigma) and expanded.Knockdown efficiency was tested by qPCR as described below.Membranes were blocked with Odyssey Blocking Buffer (TBS; LI-COR Bioscience) for 1 hour at room temperature and incubated with the primary antibody (1:500-1:1000 in TBS-T, Supplementary Table S11) overnight at 4°C.After washing the membranes for 3x10 minutes they were incubated with the secondary goat anti-mouse or goat anti-rabbit AB coupled infrared (IR) dye 680 RD or 800 CW (LI-COR, 1:10,000) for 1 hour and, after another 3 washing steps, membranes were imaged using the Odyssey Imaging System (LI-COR).

RNA extraction and qPCR
Total RNA was extracted from cells using RNeasy Kits (QIAGEN) with on-column DNase digestion, of which 1 µg was reverse transcribed into cDNA using the SensiFAST cDNA Synthesis Kit (Meridian Bioscience).Transcript abundance was measured by real-time quantitative PCR (qPCR) using the SYBR Green qPCR assay (Applied Biosystems) on the LightCycler 480 (Roche), with each PCR performed in triplicate.Primer sequences are listed in Supplementary Table S12.Gene expression was estimated using the comparative threshold cycle method 21 (delta-delta Ct) against the average Ct value obtained for two control genes (GAPDH and HPRT).

Cell viability assay
Cells were seeded at a density of 1 to 8x10 3 per well, depending on growth rates, in 384-well
After 12 hours, duplicate wells were treated with cisplatin, paclitaxel or a combination of both drugs at the respective IC50 drug concentration, as determined by the 72-hour viability assay.
Cells treated with media alone and with DMF solvent containing media served as controls.
After 16 days, cells were rinsed with PBS, fixed and stained with 0.1% crystal violet and methanol for 20 minutes.The whole area of wells was captured in bright-field at 2x magnification using the CX7 (Thermo Fisher Scientific) and the number of clones assessed with the CellProfiler v3.0 software.

Cell proliferation rates
Cells were counted using the Countess 3 Automated Cell Counter (Thermo Fisher Scientific) and seeded in 200 μl media in 96-well Corning® plates in triplicate wells and incubated at 37°C.Cells were plated at three different densities (AOCS1 6x10 3 to 8x10 3 cells/well, AOCS7.2 8 to 12x10 3 cells/well; AOCS16 14 to 18x10 3 cells/well) according to a previously observed 20% cell confluency per well on day 1, and media changed after 5 days.The whole well area was captured in brightfield every 12 hours for 9 days using real-live cell imaging (Incucyte® Zoom) and cell proliferation rates determined with Incucyte® software.Growth rates were analysed separately in triplicate wells with a starting confluency of between 15% and 25% in three independent experiments.

Cell cycle profiling
Cells were seeded in 12-well Corning® plates at between 8 to 12x10 4 cells/well (AOCS1 8x10 4 , AOCS7.2 10x10 4 , AOCS16 12x10 4 cells).After 24 hours, each cell line was treated at half the concentration of the respective IC50 (determined in the above-described cell viability assay) of either cisplatin (AOCS1: 0.25 μM, AOCS7.2:0.25 μM; AOCS16: 0.15 μM), paclitaxel (AOCS1: 1.25 nM; AOCS7.2:50 nM; AOCS16: 0.4 nM) or a combination of both drugs for 24 hours.Cells were rinsed with PBS, trypsinised to form a single-cell suspension and fixed by adding ice-cold 70% ethanol drop-wise.Cells were pelleted and resuspended in a solution containing propidium iodide (0.05 mg/ml) and ribonuclease A (RNase A, Thermo Fisher EN0531, 10 mg/ml).Following 30 to 60 minutes of incubation at room temperature, DNA content was measured using the FACS Canto LSR II flow cytometer.FlowlogicTM software (Inivai) was used to analyse cell cycle distribution in FL3-A channel applying the Watson pragmatic algorithm 22 .
no staining and lack of internal control

15 . 1 )
was used to perform gene set enrichment analyses across comparison groups.Gene level Benjamini-Hochberg adjusted P values obtained from DESeq2 were transformed to signed P values by converting them to a negative log10 value and applying the sign of the fold change.The signed P values were pre-sorted and fed into FGSEA via its function fgseaMultilevel (minSize=15, maxSize = 500, gseaParam = 0, eps = 0) to generate enrichment scores and adjusted P values using the MSigDB 5 Hallmark gene sets (v7.4).
microtiter plates (Corning®) and incubated overnight.Cisplatin (100 µM; Selleck Chemicals) and olaparib (80 µM, Selleck Chemicals) were diluted in 3-fold steps to create a 10-point dose curve; paclitaxel (0.3 µM, Selleck Chemicals) was diluted in 4-fold steps to create a 12-point dose curve.Following 72 hr (cisplatin and paclitaxel) or 120 hr incubation (olaparib), cells were fixed in 2% paraformaldehyde for 10 minutes, washed with PBS and stained with 0.19% Triton X solution containing DAPI (1:1000; SIGMA).Cell dispensing, media changes, and fixing and staining of cells were conducted robotically (BioTek Instruments, Winooski, VT, USA).Drug dispensing was performed with ALH3000 Liquid Handler (PerkinElmer, Waltham, MA, USA).To assess cell viability, the whole area of each well was captured at 10x magnification with CX7-LZR instrument (Thermo Fisher Scientific) and images analysed with CellProfiler v3.0 pipeline.Low quality out-of-focus images (4% of total images) were excluded by manual review before downstream analysis.Non-linear regression drug curves were calculated using GraphPad Prism version 9.3.1 and curve fit compared between RB1 WT and RB1 KO clones by an extra sum-of-squares F test.